Effect of adherence and insulin delivery system on clinical and economic outcomes among patients with type 2 diabetes initiating insulin treatment

Value in Health

Volumn 18, Issue 2, 2015, Pages 198-205

  Ayyagari, Rajeev ^a   Wei, Wenhui ^b   Cheng, David ^a   Pan, Chunshen ^c   Signorovitch, James ^a   Wu, Eric Q ^a  

^a ANALYSIS GROUP   (United States)

^b SANOFI   (France)

^c ProUnlimited   (United States)

Author keywords

adherence; health care costs; insulin; type 2 diabetes mellitus

Indexed keywords

HEMOGLOBIN A1C; INSULIN; ANTIDIABETIC AGENT;

ADULT; ARTICLE; CHARLSON COMORBIDITY INDEX; COMORBIDITY; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEALTH CARE COST; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; INSULIN INJECTION PEN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PREFERRED PROVIDER ORGANIZATION; PRIORITY JOURNAL; SYRINGE; AGED; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEM; ECONOMICS; FEE; PROCEDURES; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEMS; FEES, PHARMACEUTICAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84924985477     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2014.12.016     Document Type: Article

References (28)

1. U.S. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Vol. 3. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011. Available from: http://www.cdc.gov/diabetes/pubs/estimates11.htm. [Accessed March 13, 2013].
2. Williams Textbook of Endocrinology H.M. Kronenberg, S. Melmed, and K.S. Polonsky 11th ed. 2007 Elsevier Health Sciences Philadelphia, Pa
3. S.E. Inzucchi, R.M. Bergenstal, and J.B. Buse Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 35 2012 1364 1379
4. H.W. Rodbard, P.S. Jellinger, and J.A. Davidson Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control Endocr Pract 15 2009 540 559
5. American Diabetes Association Standards of medical care in diabetes - 2013 Diabetes Care 36 Suppl. 1 2013 S11 S66
6. L.A. Donnelly, A.D. Morris, and J.M.M. Evans Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes QJM 100 2007 345 350
7. O. Baser, J. Bouchard, and T. DeLuzio Assessment of adherence and healthcare costs of insulin device (FlexPen) versus conventional vial/syringe Adv Ther 27 2010 94 104
8. M. Peyrot, A.H. Barnett, and L.F. Meneghini Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study Diabet Med 29 2012 682 689
9. W. Wei, C. Pan, and L. Xie Association of treatment persistence and adherence with real-world outcomes among insulin-treated patients with type 2 diabetes mellitus (T2DM) Diabetes 61 2012 A4
10. T.L. Pearson Practical aspects of insulin pen devices J Diabetes Sci Technol 4 2010 522 531
11. R.R. Rubin, and M. Peyrot Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies Diabetes Care 27 2004 2495 2497
12. M. Korytkowski, D. Bell, and C. Jacobsen A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus Clin Ther 25 2003 2836 2848
13. W.C. Lee, S. Balu, and D. Cobden Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther 28 2006 1712 1725 discussion 1710-1
14. D. Cobden, W.C. Lee, and S. Balu Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus Pharmacotherapy 27 2007 948 962
15. M.D. Pawaskar, F.T. Camacho, and R.T. Anderson Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis Clin Ther 29 2007 1294 1305
16. N.J. Bohannon Insulin delivery using pen devices: simple-to-use tools may help young and old alike. Postgrad Med 106 1999 68 57-8, 61-4
17. J.M. Robins, M.A. Hernán, and B. Brumback Marginal structural models and causal inference in epidemiology Epidemiology 11 2000 550 560
18. M.A. Hernán, B. Brumback, and J.M. Robins Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men Epidemiology 11 2000 561 570
19. L.M. Bodnar Marginal structural models for analyzing causal effects of time-dependent treatments: an application in perinatal epidemiology Am J Epidemiol 159 2004 926 934
20. S.R. Cole Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models Am J Epidemiol 158 2003 687 694
21. R. Neugebauer, B. Fireman, and J.A. Roy Dynamic marginal structural modeling to evaluate the comparative effectiveness of more or less aggressive treatment intensification strategies in adults with type 2 diabetes Pharmacoepidemiol Drug Saf 21 Suppl. 2 2012 99 113
22. R. Neugebauer, B. Fireman, and J.A. Roy Impact of specific glucose-control strategies on microvascular and macrovascular outcomes in 58,000 adults with type 2 diabetes Diabetes Care 36 2013 3510 3516
23. A. Nandi, M.M. Glymour, and I. Kawachi Using marginal structural models to estimate the direct effect of adverse childhood social conditions on onset of heart disease, diabetes, and stroke Epidemiology 23 2012 223 232
24. L. Xie, W. Wei, and C. Pan A real-world study of patients with type 2 diabetes initiating basal insulins via disposable pens Adv Ther 28 2011 1000 1011
25. S.R. Cole, M.A. Hernán, and M.A. Herna Constructing inverse probability weights for marginal structural models Am J Epidemiol 168 2008 656 664
26. T. Asakura, and K.H. Jensen Comparison of intuitiveness, ease of use, and preference in two insulin pens J Diabetes Sci Technol 3 2009 312 319
27. M.R. Graff, and M.A. McClanahan Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe Clin Ther 20 1998 486 496
28. A.P. Yu, Y.F. Yu, and M.B. Nichol Estimating the effect of medication adherence on health outcomes among patients with type 2 diabetes - an application of marginal structural models Value Health 13 2010 1038 1045